Logo image of STRM

STREAMLINE HEALTH SOLUTIONS (STRM) Stock Fundamental Analysis

NASDAQ:STRM - US86323X2053 - Common Stock

5.3332 USD
-0.01 (-0.13%)
Last: 8/11/2025, 8:05:02 PM
Fundamental Rating

1

STRM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. STRM has a bad profitability rating. Also its financial health evaluation is rather negative. STRM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

STRM had negative earnings in the past year.
STRM had a negative operating cash flow in the past year.
STRM had negative earnings in 4 of the past 5 years.
STRM had a negative operating cash flow in each of the past 5 years.
STRM Yearly Net Income VS EBIT VS OCF VS FCFSTRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M -15M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.30%, STRM is in line with its industry, outperforming 41.67% of the companies in the same industry.
STRM has a Return On Equity of -82.00%. This is in the lower half of the industry: STRM underperforms 69.44% of its industry peers.
Industry RankSector Rank
ROA -25.3%
ROE -82%
ROIC N/A
ROA(3y)-30.62%
ROA(5y)-20.25%
ROE(3y)-71.39%
ROE(5y)-46.33%
ROIC(3y)N/A
ROIC(5y)N/A
STRM Yearly ROA, ROE, ROICSTRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 48.29%, STRM is in line with its industry, outperforming 41.67% of the companies in the same industry.
STRM's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for STRM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.74%
GM growth 5Y-3.21%
STRM Yearly Profit, Operating, Gross MarginsSTRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

1

2. Health

2.1 Basic Checks

STRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STRM has more shares outstanding
The number of shares outstanding for STRM has been reduced compared to 5 years ago.
STRM has a worse debt/assets ratio than last year.
STRM Yearly Shares OutstandingSTRM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
STRM Yearly Total Debt VS Total AssetsSTRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

STRM has an Altman-Z score of -5.15. This is a bad value and indicates that STRM is not financially healthy and even has some risk of bankruptcy.
STRM has a worse Altman-Z score (-5.15) than 75.00% of its industry peers.
STRM has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
STRM has a Debt to Equity ratio of 0.18. This is comparable to the rest of the industry: STRM outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -5.15
ROIC/WACCN/A
WACC10.21%
STRM Yearly LT Debt VS Equity VS FCFSTRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

STRM has a Current Ratio of 0.27. This is a bad value and indicates that STRM is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.27, STRM is doing worse than 91.67% of the companies in the same industry.
STRM has a Quick Ratio of 0.27. This is a bad value and indicates that STRM is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of STRM (0.27) is worse than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.27
STRM Yearly Current Assets VS Current LiabilitesSTRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

STRM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -127.84%.
Looking at the last year, STRM shows a very negative growth in Revenue. The Revenue has decreased by -14.88% in the last year.
The Revenue has been growing by 8.60% on average over the past years. This is quite good.
EPS 1Y (TTM)-127.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.52%
Revenue 1Y (TTM)-14.88%
Revenue growth 3Y0.99%
Revenue growth 5Y8.6%
Sales Q2Q%11.09%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
STRM Yearly Revenue VS EstimatesSTRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
STRM Yearly EPS VS EstimatesSTRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

STRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STRM Price Earnings VS Forward Price EarningsSTRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STRM Per share dataSTRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for STRM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STREAMLINE HEALTH SOLUTIONS

NASDAQ:STRM (8/11/2025, 8:05:02 PM)

5.3332

-0.01 (-0.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)06-16 2025-06-16
Earnings (Next)09-09 2025-09-09
Inst Owners26.05%
Inst Owner Change108.6%
Ins Owners17.45%
Ins Owner Change-4.24%
Market Cap23.25M
Analysts82.86
Price TargetN/A
Short Float %0.38%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.27
P/FCF N/A
P/OCF N/A
P/B 2.1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS4.22
BVpS2.54
TBVpS-3.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.3%
ROE -82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.29%
FCFM N/A
ROA(3y)-30.62%
ROA(5y)-20.25%
ROE(3y)-71.39%
ROE(5y)-46.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.74%
GM growth 5Y-3.21%
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.98%
Cap/Sales 4.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.27
Altman-Z -5.15
F-Score4
WACC10.21%
ROIC/WACCN/A
Cap/Depr(3y)33.38%
Cap/Depr(5y)45.96%
Cap/Sales(3y)6.59%
Cap/Sales(5y)8.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-127.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.52%
EPS Next Y15.38%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-14.88%
Revenue growth 3Y0.99%
Revenue growth 5Y8.6%
Sales Q2Q%11.09%
Revenue Next Year4.04%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year135.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.63%
OCF growth 3YN/A
OCF growth 5YN/A